Publications
Detailed Information
Cell growth inhibitory and anti-cancer adjuvant effects of KG-135, the standardized formulation of ginseng, in HeLa cells : 열처리-가공 인삼사포닌 (KG-135)의 세포 성장 억제 및 항암 보조 효과에 관한 연구
DC Field | Value | Language |
---|---|---|
dc.contributor.advisor | 서영준 | - |
dc.contributor.author | 이원희 | - |
dc.date.accessioned | 2010-05-06T03:51:51Z | - |
dc.date.available | 2010-05-06T03:51:51Z | - |
dc.date.copyright | 2010 | - |
dc.date.issued | 2010 | - |
dc.identifier.uri | http://dcollection.snu.ac.kr:80/jsp/common/DcLoOrgPer.jsp?sItemId=000000032432 | eng |
dc.identifier.uri | https://hdl.handle.net/10371/64113 | - |
dc.description | Thesis(doctors) --서울대학교 대학원 :약학과(의약생명과학전공),2010.2. | en |
dc.format.extent | xi, 147 leaves | en |
dc.language.iso | en | en |
dc.publisher | 서울대학교 대학원 | en |
dc.subject | 세포자살. G1기 | en |
dc.subject | apoptosis | en |
dc.subject | Cyclin | en |
dc.subject | G1 phase | en |
dc.subject | Cdk 복합체 | en |
dc.subject | Cyclin | en |
dc.subject | 프로테아좀 관련 분해 | en |
dc.subject | Cdk complex | en |
dc.subject | etoposide | en |
dc.subject | proteasome-mediated degradation | en |
dc.subject | p53 | en |
dc.subject | etoposide | en |
dc.subject | 21Waf1 | en |
dc.subject | p53 | en |
dc.subject | Cip1 | en |
dc.subject | p21Waf1 | en |
dc.subject | p27Kip1 | en |
dc.subject | Cip1 | en |
dc.subject | Bax | en |
dc.subject | p27Kip1 | en |
dc.subject | 미토콘드리아 막 전위 | en |
dc.subject | Bax | en |
dc.subject | 보조제 | en |
dc.subject | mitochondrial transmembrane potential | en |
dc.subject | adjuvant | en |
dc.title | Cell growth inhibitory and anti-cancer adjuvant effects of KG-135, the standardized formulation of ginseng, in HeLa cells | en |
dc.title.alternative | 열처리-가공 인삼사포닌 (KG-135)의 세포 성장 억제 및 항암 보조 효과에 관한 연구 | en |
dc.type | Thesis | - |
dc.contributor.department | 약학과(의약생명과학전공) | - |
dc.description.degree | Doctor | en |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.